Daly Richard J — SEC insider filings
SEC reporting owner CIK 1635393. 32 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-12-28 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 28,025 shares, $99,331 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 110,293 shares, $2,490,576 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 75.
- Largest priced transaction: sale of 70,000 shares @ $24.86 ($1,740,200) in CATALYST PHARMACEUTICALS, INC., filed 2025-06-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. (CPRX) | President and CEO, Director | 26 | — | 3 legs · 110,293 sh · $2,490,576 | 65 |
| Aquestive Therapeutics, Inc. (AQST) | Director | 3 | 2 legs · 28,025 sh · $99,331 | — | 1 |
| OPIANT PHARMACEUTICALS, INC. (OPNT) | Director | 3 | — | — | 9 |
Insider filings — Daly Richard J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | Aquestive Therapeutics, Inc. (AQST) | Purchase (P): 1,200 @ $3.53 · Purchase (P): 26,825 @ $3.54 | EDGAR |
| 2026-11-10 | 4 | Aquestive Therapeutics, Inc. (AQST) | Grant/award (A): 57,000 (derivative) @ $0 | EDGAR |
| 2026-10-16 | 3 | Aquestive Therapeutics, Inc. (AQST) | Holdings only — no transactions reported | EDGAR |
| 2026-07-17 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Disposition to issuer (D): 271,266 @ $31.50 · Disposition to issuer (D): 33,500 (derivative) @ $0 · Disposition to issuer (D): 30,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 15,000 (derivative) @ $0 · Disposition to issuer (D): 1,365,319 (derivative) @ $0 · +5 more | EDGAR |
| 2026-01-06 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 42,105 · Tax withholding (F): 10,577 · Option exercise (M): 42,105 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,334 · Tax withholding (F): 524 · Option exercise (M): 1,334 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 20,006 · Tax withholding (F): 7,872 · Grant/award (A): 381,948 (derivative) @ $0 · Grant/award (A): 115,283 (derivative) @ $0 · Option exercise (M): 20,006 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 50,000 @ $2.24 · Sale (S): 22,970 @ $20.62 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Sale (S): 70,000 @ $24.86 | EDGAR |
| 2025-02-19 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 4,000 · Tax withholding (F): 1,574 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 42,105 · Tax withholding (F): 10,600 · Option exercise (M): 42,105 (derivative) @ $0 | EDGAR |
| 2024-12-31 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,333 · Tax withholding (F): 324 · Option exercise (M): 1,333 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 491,160 (derivative) @ $0 · Grant/award (A): 60,019 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 40,000 @ $4.01 · Sale (S): 17,323 @ $15.97 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 4,000 · Tax withholding (F): 1,186 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 1,365,319 (derivative) @ $0 · Grant/award (A): 210,526 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,333 · Option exercise (M): 1,333 (derivative) @ $0 | EDGAR |
| 2023-12-11 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 60,000 @ $1.13 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2023-05-16 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 50,000 @ $0.79 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | OPIANT PHARMACEUTICALS, INC. (OPNT) | Disposition to issuer (D): 5,800 @ $20 · Disposition to issuer (D): 2,000 @ $20 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 4,000 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2022-12-29 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2022-12-08 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,334 · Option exercise (M): 1,334 (derivative) @ $0 | EDGAR |
| 2022-08-26 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 40,000 @ $2.53 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-14 | 4 | OPIANT PHARMACEUTICALS, INC. (OPNT) | Grant/award (A): 2,000 @ $0 | EDGAR |
| 2022-02-16 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 50,000 @ $3.35 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2021-12-30 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-12-06 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,333 · Option exercise (M): 1,333 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | OPIANT PHARMACEUTICALS, INC. (OPNT) | Grant/award (A): 2,000 @ $0 · Grant/award (A): 2,500 (derivative) @ $0 | EDGAR |
| 2021-01-04 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2020-12-28 | 4 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Option exercise (M): 1,333 · Option exercise (M): 1,333 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1635393 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs